Streetbeat News

Products Services

MCHP

Microchip Technology Inc. (NASDAQ:MCHP) has completed the acquisition of VSI Co. Ltd., a Seoul, Korea-based pioneer in automotive networking technologies, to enhance its leadership in the automotive networking market. The acquisition aims to address the growing demand for Advanced Driver Assistance Systems (ADAS) and digital cockpit connectivity, leveraging the Automotive SerDes Alliance (ASA) open standard. The automotive radar, camera, and LiDAR modules market is expected to double in revenue by 2028, driven by the adoption of ADAS and next-generation software-defined vehicles (SDV). VSI's expertise in ASA Motion Link technologies will complement Microchip's automotive networking portfolio, supporting the industry's shift towards Ethernet, PCIe, and ASA Motion Link standards.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:09 pm

FCEL

FuelCell Energy, Inc. (NASDAQ:FCEL) will use its carbonate fuel cell technology in a Sacramento Sewer biogeneration project developed by Ameresco to convert biofuel into clean electricity. The project will utilize a 2.8-Megawatt fuel cell platform capable of producing power and heat from biogas, with potential for renewable green hydrogen production. FuelCell Energy will also provide comprehensive maintenance services for the system. This initiative supports community facilities in producing efficient, clean electricity, reducing greenhouse gas emissions, and helping local governments meet sustainability goals.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:08 pm

HRMY

Harmony Biosciences (HRMY) has entered into an exclusive licensing agreement with Bioprojet to develop and commercialize TPM-1116, a promising oral orexin-2 receptor agonist for treating narcolepsy and other sleep/wake disorders. Harmony will pay Bioprojet $25.5 million upfront, with potential future payments totaling up to $367.5 million based on development, regulatory, and sales milestones, plus mid-teen royalties on sales. This agreement aims to bolster Harmony's position in the sleep/wake disorder market by leveraging the potential of TPM-1116 to offer a best-in-class clinical profile.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:07 pm

NVEE

NV5 has been awarded contracts totaling $13 million for the expansion of data center assets for technology and financial companies in Asia and the US. This development indicates NV5's growing influence in the tech and financial sectors' infrastructure projects.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:06 pm

MEIP

MEI Pharma, Inc. (NASDAQ:MEIP) has decided to focus on advancing voruciclib and developing a new formulation of ME-344 based on positive clinical data, foregoing a second capital return under the 2023 Anson and Cable Car Cooperation Agreement to conserve capital. The strategic plan aims to optimize the development of voruciclib for a Phase 3 study in combination with venetoclax for treating relapsed/refractory AML and to enhance ME-344's formulation for treating solid tumors in combination with VEGF inhibitors like Avastin. This decision is aligned with the company's goal to address significant medical needs while managing resources effectively.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:06 pm

BHC

Bausch Health Companies Inc. (NYSE:BHC) announced that its acne treatment, PrARAZLO, is now available through British Columbia's public drug plan, BC PharmaCare. PrARAZLO, a tazarotene lotion, is the only Health Canada-approved acne treatment of its kind for patients aged 10 and older. The availability across all public drug plans in Canada marks a significant step for Bausch Health in expanding access to their dermatology portfolio. PrARAZLO utilizes PRISMATREX technology to reduce skin dryness, a common side effect, potentially improving patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:04 pm

BTCUSD

Matt Hougan, CIO of Bitwise Asset Management, argues that Bitcoin's price is influenced by both speculation and its increasing real-world utility. He envisions a future where Bitcoin's value is primarily driven by its utility rather than speculation. Hougan highlights the growing adoption of Bitcoin as a hedge against currency devaluation and its legitimacy boost from the launch of Bitcoin ETFs. He suggests that Bitcoin's utility and adoption will continue to grow, potentially reshaping the global financial landscape.

Portfolio Pulse from Murtuza Merchant

April 11, 2024 | 11:55 am

GSK

PDCO

PFE

Wall Street's most accurate analysts have provided their views on three health care stocks with over 3% dividend yields: Pfizer Inc. (PFE), GSK plc (GSK), and Patterson Companies, Inc. (PDCO). Pfizer's recent Phase 3 trial data, GSK's collaboration with CureVac on a seasonal influenza vaccine, and Patterson Companies' $500 million stock buyback and dividend declaration are highlighted as recent news affecting these stocks.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 11:48 am

RAMP

Cross Screen Media has announced a strategic partnership with LiveRamp (NYSE:RAMP) to enhance video ad targeting and measurement for local agencies. This collaboration aims to improve Cross Screen Media's capabilities and prepare for a cookieless future by utilizing LiveRamp's identity resolution and transcoding app, Powered by Snowflake, ensuring compliance with privacy measures.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:47 am

INDP

Indaptus Therapeutics revealed details about its Decoy Platform's mechanism of action at the AACR Research Annual Meeting, showing it activates multiple immune cell types for anti-tumor responses.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:35 am